12:00 AM
 | 
Dec 24, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Chantix regulatory update

FDA issued a drug safety communication warning that a pooled analysis of clinical trials of Pfizer's Chantix varenicline showed a higher occurrence of major adverse...

Read the full 102 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >